Scholar Rock Holding Co. (NASDAQ:SRRK) Given Average Recommendation of “Buy” by Analysts

Shares of Scholar Rock Holding Co. (NASDAQ:SRRK) have earned a consensus rating of “Buy” from the seven ratings firms that are currently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $40.43.

Several equities analysts have recently weighed in on the company. Piper Sandler raised their price target on Scholar Rock from $28.00 to $42.00 and gave the company an “overweight” rating in a report on Tuesday, October 15th. BMO Capital Markets raised their price target on Scholar Rock from $34.00 to $38.00 and gave the company an “outperform” rating in a report on Friday, October 11th. Wedbush restated an “outperform” rating and set a $47.00 price target on shares of Scholar Rock in a report on Thursday, January 9th. Truist Financial raised their price target on Scholar Rock from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday, November 25th. Finally, HC Wainwright lifted their price objective on Scholar Rock from $40.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th.

Insider Buying and Selling at Scholar Rock

In other Scholar Rock news, General Counsel Junlin Ho sold 9,039 shares of the business’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $44.20, for a total transaction of $399,523.80. Following the completion of the sale, the general counsel now directly owns 195,037 shares in the company, valued at $8,620,635.40. The trade was a 4.43 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Public Equities L.P. Invus sold 409,433 shares of the business’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $38.49, for a total value of $15,759,076.17. Following the sale, the insider now owns 10,850,005 shares of the company’s stock, valued at approximately $417,616,692.45. This represents a 3.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 458,974 shares of company stock worth $17,948,788 in the last three months. 19.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. GAMMA Investing LLC lifted its position in shares of Scholar Rock by 51.8% during the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock valued at $34,000 after buying an additional 269 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Scholar Rock by 1.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company’s stock valued at $310,000 after buying an additional 379 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Scholar Rock by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,895 shares of the company’s stock valued at $25,000 after buying an additional 514 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in shares of Scholar Rock by 1,321.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock valued at $48,000 after buying an additional 1,031 shares in the last quarter. Finally, Cinctive Capital Management LP lifted its position in shares of Scholar Rock by 7.2% during the 3rd quarter. Cinctive Capital Management LP now owns 42,902 shares of the company’s stock valued at $344,000 after buying an additional 2,869 shares in the last quarter. 91.08% of the stock is owned by hedge funds and other institutional investors.

Scholar Rock Price Performance

Shares of NASDAQ:SRRK opened at $44.88 on Wednesday. Scholar Rock has a 1-year low of $6.76 and a 1-year high of $46.19. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. The business has a fifty day moving average price of $39.94 and a 200-day moving average price of $23.59. The company has a market capitalization of $4.20 billion, a PE ratio of -19.10 and a beta of 0.52.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.